Literature DB >> 2997178

The relationship between gastric acid secretion and gastric H+,K+-ATPase activity.

B Wallmark, H Larsson, L Humble.   

Abstract

The H+,K+-ATPase has been postulated to be the enzyme responsible for H+ secretion by the parietal cell. Omeprazole has been shown to be an inhibitor of acid secretion in vivo, but also in in vitro test models for acid secretion, including partly purified H+,K+-ATPase, the inhibitory action of omeprazole has been demonstrated (Wallmark, B., Jaresten, B. M., Larsson, H., Ryberg, B., Brändström, A., and Fellenius, E. (1983) Am. J. Physiol. 245, G64-G71). It was thus possible to use this compound to demonstrate a correlation between H+,K+-ATPase activity in rat oxyntic mucosa and in vivo H+ secretion. Two results were found. (a) Increasing oral doses of omeprazole progressively inhibited acid secretion, H+,K+-ATPase activity, and phosphoenzyme formation of a microsomal fraction isolated from the inhibited rat mucosa. Furthermore, a Mg2+-stimulated ATPase activity, associated with the H+,K+-ATPase membrane fraction, was not affected by the omeprazole treatment. (b) Recovery of H+,K+-ATPase activity following complete omeprazole inhibition was correlated with the appearance of acid secretion. The results indicate a strict relationship between the activity of the gastric H+,K+-ATPase in the microsomal fraction and gastric acid secretion.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2997178

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

Review 1.  Acid-base transport systems in gastrointestinal epithelia.

Authors:  D Gleeson
Journal:  Gut       Date:  1992-08       Impact factor: 23.059

Review 2.  Molecular mechanisms in therapy of acid-related diseases.

Authors:  J M Shin; O Vagin; K Munson; M Kidd; I M Modlin; G Sachs
Journal:  Cell Mol Life Sci       Date:  2008-01       Impact factor: 9.261

3.  Peptic ulcer disease. Pathophysiology and current medical management.

Authors:  B F Scharschmidt
Journal:  West J Med       Date:  1987-06

Review 4.  Omeprazole: a pharmacoeconomic evaluation of its use in duodenal ulcer and reflux oesophagitis.

Authors:  L B Barradell; D McTavish
Journal:  Pharmacoeconomics       Date:  1993-06       Impact factor: 4.981

5.  Ouabain-insensitive K-adenosine triphosphatase in distal nephron segments of the rabbit.

Authors:  L C Garg; N Narang
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

6.  Cibenzoline, an ATP-sensitive K(+) channel blocker, binds to the K(+)-binding site from the cytoplasmic side of gastric H(+),K(+)-ATPase.

Authors:  Y Tabuchi; H Yashiro; S Hoshina; S Asano; N Takeguchi
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

Review 7.  Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders.

Authors:  D McTavish; M M Buckley; R C Heel
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

8.  Cysteamine increases expression and activity of H+-K+-ATPase of gastric mucosal cells in weaning piglets.

Authors:  Zhi-Min Shi; Gai-Mei Du; Xi-Hui Wei; Lei Zhang; Jie Chen; Ru-Qian Zhao
Journal:  World J Gastroenterol       Date:  2005-11-14       Impact factor: 5.742

9.  Famotidine, a histamine-2-receptor antagonist, inhibits the increase in rat gastric H+/K(+)-ATPase mRNA induced by intravenous infusion of gastrin 17 and histamine.

Authors:  G Yamamoto; A Tari; K Sumii; M Sumii; K Haruma; G Kajiyama
Journal:  Dig Dis Sci       Date:  1995-09       Impact factor: 3.199

Review 10.  The gastric HK-ATPase: structure, function, and inhibition.

Authors:  Jai Moo Shin; Keith Munson; Olga Vagin; George Sachs
Journal:  Pflugers Arch       Date:  2008-06-06       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.